A study to see if enzalutamide could help patients with prostate cancer have more time before their cancer starts to spread to other parts of the body or dying from any cause
PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Category & Conditions: Cancer
Medicine: Xtandi (enzalutamide)
ClinicalTrials.gov Identifier (NCT): NCT02003924
Protocol ID: C3431005
PrintDownloadOpen Plain Language Summary Result: Click here